Publications

Year of Publicationsort descending Title Faculty Association
2010 Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Roberta Diaz Brinton, Ph.D
2011 Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Roberta Diaz Brinton, Ph.D
2011 Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons: antagonism by progesterone. Roberta Diaz Brinton, Ph.D
2011 Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Roberta Diaz Brinton, Ph.D
2011 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Roberta Diaz Brinton, Ph.D
2011 Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2011 The effect of dietary soy isoflavones before and after ovariectomy on hippocampal protein markers of mitochondrial bioenergetics and antioxidant activity in female monkeys. Roberta Diaz Brinton, Ph.D
2011 Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Roberta Diaz Brinton, Ph.D
2011 Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2011 The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Roberta Diaz Brinton, Ph.D
2011 Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2011 Development of potent μ and δ opioid agonists with high lipophilicity. Frank Porreca, PhD, Todd Vanderah, PhD
2011 Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats. Tally Largent-Milnes, PhD, Todd Vanderah, PhD
2011 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2011 Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. John M. Streicher, PhD
2011 Membrane estrogen receptors mediate calcium signaling and MAP kinase activation in individual hippocampal neurons. Roberta Diaz Brinton, Ph.D
2011 Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Peg Davis, Victor Hruby, Ph.D., Josephine Lai , Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2011 Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Roberta Diaz Brinton, Ph.D
2011 Hippocampal responsiveness to 17β-estradiol and equol after long-term ovariectomy: implication for a therapeutic window of opportunity. Roberta Diaz Brinton, Ph.D
2011 Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Frank Porreca, PhD, Todd Vanderah, PhD
2012 A dominant negative ERβ splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy in rats. Roberta Diaz Brinton, Ph.D
2012 Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. Tally Largent-Milnes, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2012 Intranasal delivery of biologics to the central nervous system. Jeffrey J. Lochhead, PhD
2012 Minireview: translational animal models of human menopause: challenges and emerging opportunities. Roberta Diaz Brinton, Ph.D
2012 Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Frank Porreca, PhD, Todd Vanderah, PhD

Pages